AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE) both reported fourth quarter earnings in early February. AbbVie posted record net ...
Pharmaceutical companies AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE) both reported fourth-quarter earnings in early February, ...
The choice is based on more than just the dividend payout.
StockStory.org on MSN
Q4 earnings highs and lows: Pfizer (NYSE:PFE) vs the rest of the branded pharmaceuticals stocks
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...
Pfizer is facing patent cliffs on multiple drugs in the next few years. The company has been making big acquisitions to ...
Dividend stocks are a great way for investors to generate passive income that can be more reliable and predictable than investing in stocks for pure appreciation. While there are no guarantees in the ...
If you are wondering whether Pfizer at around US$27.47 is a bargain or a value trap, the key is understanding what the current price actually implies about the company. The stock is up 9.1% year to ...
Pfizer’s recent bidding war for an obesity biotech clearly hasn’t satiated the pharma’s appetite for new GLP-1 therapies—at least going by this morning’s $1.9 billion biobucks deal. The U.S. drugmaker ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results